Related Experiment Video
Updated: Feb 3, 2026

Author Spotlight: Advancing Cardiovascular Imaging - Introducing the Spatially Weighted Calcium Score for Early Disease Detection
Published on: September 22, 2023
Risk stratification using coronary artery calcium and potential benefit of semaglutide therapy: A cost-effectiveness
Sai Rahul Ponnana1, Tong Zhang1, Santosh Kumar Sirasapalli1
1Case School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Insights
Coronary artery calcium (CAC) scoring helps predict major adverse cardiovascular events (MACE) risk. This study found semaglutide therapy is more cost-effective for individuals with higher CAC scores, suggesting CAC can guide treatment decisions.
Area of Science:
- Cardiovascular Medicine
- Pharmacoeconomics
- Obesity Management
Background:
- Coronary artery calcium (CAC) scoring effectively stratifies risk for major adverse cardiovascular events (MACE).
- Semaglutide is a highly effective anti-obesity medication, but its high cost limits accessibility.
- Cost-effectiveness of semaglutide therapy in relation to CAC scores requires investigation.
Purpose of the Study:
- To evaluate the cost-effectiveness of semaglutide treatment across different coronary artery calcium (CAC) scoring groups.
- To determine the clinical benefit and economic value of semaglutide based on CAC-defined cardiovascular risk.
Main Methods:
- Utilized data from 38,058 CLARIFY registry participants meeting SELECT criteria, stratified by CAC score (0, 1-99, 100-399, ≥400).
- Estimated MACE risk using multivariable-adjusted Cox proportional hazard models.
- Developed lifetime-horizon Markov models to simulate semaglutide therapy, calculating number needed to treat (NNT) and incremental cost-effectiveness ratios (ICER).
Main Results:
- Higher CAC scores correlated with increased MACE risk, including myocardial infarction, heart failure, stroke, and all-cause mortality.
- Semaglutide therapy showed potential MACE NNT values of 151 for CAC=0 and 34 for CAC≥400 over 3.3 years.
- The incremental cost-effectiveness ratio (ICER) for semaglutide decreased significantly with higher CAC scores, from $625,863/QALY for CAC=0 to $168,666/QALY for CAC≥400.
Conclusions:
- Coronary artery calcium (CAC) scoring can serve as a valuable tool for assessing the potential clinical benefits and cost-effectiveness of lifelong semaglutide therapy in obese individuals.
- CAC scoring may aid in personalizing treatment strategies for semaglutide to optimize outcomes and resource allocation.
Aim:
Coronary artery calcium (CAC) scoring is observed to improve risk stratification for major adverse cardiovascular events (MACE). Semaglutide, a recently introduced anti-obesity drug, is very effective, but wider use is limited due to high costs. Hence, this study investigated the cost-effectiveness (CEA) of semaglutide across CAC groups.
Materials And Methods:
CAC scores for 38 058 CLARIFY registry participants meeting SELECT criteria were included. They were stratified into four CAC groups: 0, 1-99, 100-399, ≥400. To determine MACE (composite of myocardial infarction, heart failure, stroke or all-cause mortality) risk across CAC groups, hazard ratios (HR) were estimated from multi-variable adjusted Cox proportional hazard models. Next, lifetime-horizon Markov models were created to simulate semaglutide therapy and the potential clinical benefit (reported as number needed to treat [NNT]) and CEA (estimated with incremental cost-effectiveness ratio [ICER]) were examined for CAC groups. Multiple scenarios to mimic real-world experience were fitted for robust sensitivity analyses.
Results:
Compared to CAC = 0, MACE risk was higher for CAC ≥400 (HR: 1.97 [95% CI: 1.66-2.35]), heart failure (HR: 1.76 [95% CI: 1.36-2.28]), mortality (HR: 1.62 [95% CI: 1.21-2.17]). Modelling 3.3 years of semaglutide use resulted in potential MACE NNT values of 151 (95% CI: 108-302) and 34 (95% CI: 25-69) for CAC = 0 and CAC ≥400. Markov modelled ICER for semaglutide use reduced across CAC groups ($625 863/QALY [CAC = 0] vs. $168 666/QALY [CAC ≥400]).
Conclusions:
CAC scores have potential use as a tool to estimate potential clinical benefit and cost for lifetime semaglutide therapy among obese individuals.
Related Concept Videos
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease V: Interprofessional Care
Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease IV: Preventive Measures
Benefits of Self-Esteem

